Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Estrogen Receptor Negative|GPNMB Positive|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Progesterone Receptor Negative|Stage III Breast Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Uveal Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Uveal Melanoma AJCC v7|Triple-Negative Breast Carcinoma|Unresectable Solid Neoplasm
Interventions: DRUG: Glembatumumab Vedotin|BIOLOGICAL: Ipilimumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|OTHER: Pharmacological Study
Sponsor: National Cancer Institute (NCI)